Literature DB >> 16892657

The economic burden of intracerebral hemorrhage: evidence from managed care.

Mason W Russell1, Luke Boulanger, Ashish V Joshi, Peter J Neumann, Joseph Menzin.   

Abstract

Data from the Integrated Healthcare Information Services managed care database were used to estimate per-patient costs of intracerebral hemorrhage (ICH) for up to one year after an initial ICH event. Plan enrollees (age > or = 18 yr) hospitalized with a primary International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis of ICH (431.xx) during July 1999 to June 2002 were selected. Resource utilization/costs associated with the initial hospitalization were calculated for all patients. Postdischarge use/cost of health care services (repeat hospitalization, skilled nursing/rehabilitation services, outpatient use, pharmacy) were estimated for up to 365 days after hospital discharge for patients surviving the initial stay. Forty-six percent of the 493 patients selected were at least 65 years of age and 60% had private health insurance. Patients who died during their initial ICH hospitalization (N = 189 [38.4%]) incurred average treatment costs of $16,466. Survivors incurred initial hospitalization costs of $28,360 and first-year postdischarge costs of $16,035. Among survivors, 8% had repeat hospitalizations and 41% required inpatient skilled nursing/rehabilitation. Treatment costs for ICH to private payers appear to be considerable and may reflect a sizable long-term financial burden to U.S. health plans.

Entities:  

Mesh:

Year:  2006        PMID: 16892657

Source DB:  PubMed          Journal:  Manag Care Interface        ISSN: 1096-5645


  8 in total

Review 1.  Cerebral microbleeds and macrobleeds: should they influence our recommendations for antithrombotic therapies?

Authors:  Kellen E Haley; Steven M Greenberg; M Edip Gurol
Journal:  Curr Cardiol Rep       Date:  2013-12       Impact factor: 2.931

2.  Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL.

Authors:  James V Freeman; David W Hutton; Geoffrey D Barnes; Ruo P Zhu; Douglas K Owens; Alan M Garber; Alan S Go; Mark A Hlatky; Paul A Heidenreich; Paul J Wang; Amin Al-Ahmad; Mintu P Turakhia
Journal:  Circ Arrhythm Electrophysiol       Date:  2016-06

3.  Can minimally invasive puncture and drainage for hypertensive spontaneous Basal Ganglia intracerebral hemorrhage improve patient outcome: a prospective non-randomized comparative study.

Authors:  Guo-Qiang Wang; Shi-Qiang Li; Yong-Hua Huang; Wei-Wei Zhang; Wen-Wei Ruan; Jia-Zhen Qin; Ying Li; Wei-Min Yin; Yun-Jun Li; Zheng-Jun Ren; Ji-Qiang Zhu; Yun-Yan Ding; Jun-Qi Peng; Pei-Jian Li
Journal:  Mil Med Res       Date:  2014-06-01

4.  Minimally invasive cone beam CT-guided evacuation of parenchymal and ventricular hemorrhage using the Apollo system: proof of concept in a cadaver model.

Authors:  David Fiorella; Adam Arthur; Sebastian Schafer
Journal:  J Neurointerv Surg       Date:  2014-07-01       Impact factor: 5.836

5.  Minimal invasive puncture and drainage versus endoscopic surgery for spontaneous intracerebral hemorrhage in basal ganglia.

Authors:  Zhihong Li; Yuqian Li; Feifei Xu; Xi Zhang; Qiang Tian; Lihong Li
Journal:  Neuropsychiatr Dis Treat       Date:  2017-01-25       Impact factor: 2.570

6.  Stereotactic Catheter Drainage Versus Conventional Craniotomy for Severe Spontaneous Intracerebral Hemorrhage in the Basal Ganglia.

Authors:  Jia Shi; Zhonghai Cai; Wei Han; Bo Dong; Yumin Mao; Jiachao Cao; Suinuan Wang; Wei Guan
Journal:  Cell Transplant       Date:  2019-05-27       Impact factor: 4.064

7.  Blood Pressure and Spot Sign in Spontaneous Supratentorial Subcortical Intracerebral Hemorrhage.

Authors:  Joseph A Falcone; Alex Lopez; Dana Stradling; Wengui Yu; Jefferson W Chen
Journal:  Neurocrit Care       Date:  2022-04-20       Impact factor: 3.532

Review 8.  Endoscopic treatment of hypertensive intracerebral hemorrhage: A technical review.

Authors:  Yi-Ning Zhao; Xiao-Lei Chen
Journal:  Chronic Dis Transl Med       Date:  2016-12-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.